From Surf Wiki (app.surf) — the open knowledge base
Serotonin reuptake inhibitor
Class of drug
.svg)
Class of drug
serotonin reuptake inhibitors
A serotonin reuptake inhibitor (SRI) is a type of drug which acts as a reuptake inhibitor of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) by blocking the action of the serotonin transporter (SERT). This in turn leads to increased extracellular concentrations of serotonin and, therefore, an increase in serotonergic neurotransmission. It is a type of monoamine reuptake inhibitor (MRI); other types of MRIs include dopamine reuptake inhibitors and norepinephrine reuptake inhibitors.
SRIs are not synonymous with selective serotonin reuptake inhibitors (SSRIs), as the latter term is usually used to describe the class of antidepressants of the same name, and because SRIs, unlike SSRIs, can either be selective or non-selective in their action. For example, cocaine, which non-selectively inhibits the reuptake of serotonin, norepinephrine, and dopamine, is an SRI but not an SSRI.
SRIs are used predominantly as antidepressants (e.g., SSRIs, SNRIs, and TCAs), though they are also commonly used in the treatment of other psychological conditions such as anxiety disorders and eating disorders. Less often, SRIs are also used to treat a variety of other medical conditions including neuropathic pain and fibromyalgia (e.g., duloxetine, milnacipran), and premature ejaculation (e.g., dapoxetine) as well as for dieting (e.g., sibutramine). Additionally, some clinically used drugs such as chlorpheniramine, dextromethorphan, and methadone possess SRI properties secondarily to their primary mechanism of action(s) and this contributes to their side effect and drug interaction profiles.
A closely related type of drug is a serotonin releasing agent (SRA), an example of which is fenfluramine.
Comparison of SRIs
Binding profiles
| Medication | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Citalopram | |||||||||
| Desmethylcitalopram | |||||||||
| Escitalopram | |||||||||
| Femoxetine | |||||||||
| Fluoxetine | |||||||||
| Fluvoxamine | |||||||||
| Norfluoxetine | |||||||||
| Paroxetine | |||||||||
| Sertraline | |||||||||
| Desmethylsertraline | |||||||||
| Zimelidine | |||||||||
| vauthors = Deardorff WJ, Grossberg GT | title = A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine | journal = Expert Opin Pharmacother | volume = 15 | issue = 17 | pages = 2525–42 | year = 2014 | pmid = 25224953 | doi = 10.1517/14656566.2014.960842 | s2cid = 12581442 }} |
| Venlafaxine | |||||||||
| Vilazodone | |||||||||
| Vortioxetine | |||||||||
| Amitriptyline | |||||||||
| Clomipramine | |||||||||
| Imipramine |
SERT occupancy
| Medication | author1=Gerald P. Koocher | author2=John C. Norcross | author3=Beverly A. Greene | title=Psychologists' Desk Reference | url=https://books.google.com/books?id=Ox1wAgAAQBAJ&pg=PA442 | date=2013 | publisher=Oxford University Press | isbn=978-0-19-984550-7 | pages=442–}} | ~80% SERT |
|---|---|---|---|---|---|---|---|---|---|---|
| occupancy | ||||||||||
| (mg/day) | Ratio (dosage / | |||||||||
| 80% occupancy) | ||||||||||
| Citalopram | 20–40 | 40 | 0.5–1 | |||||||
| Escitalopram | 10–20 | 10 | 1–2 | |||||||
| Fluoxetine | 20–80 | 20 | 1–4 | |||||||
| Fluvoxamine | 50–350 | 70 | 0.71–5 | |||||||
| Paroxetine | 10–60 | 20 | 0.5–3 | |||||||
| Sertraline | 25–200 | 50 | 0.5–4 | |||||||
| Duloxetine | 20–120 | 30 | 0.67–2 | |||||||
| Venlafaxine | 75–375 | 75 | 1–5 | |||||||
| Clomipramine | 50–250 | 10 | 5–25 |
List of SERT-selective SRIs
Many SRIs exist, an assortment of which are listed below. Note that only SRIs selective for the SERT over the other monoamine transporters (MATs) are listed below. For a list of SRIs that act at multiple MATs, see other monoamine reuptake inhibitor pages such as SNRI and SNDRI.
Selective serotonin reuptake inhibitors (SSRIs)
Marketed
- Citalopram (Celexa)
- Dapoxetine (Priligy)
- Escitalopram (Lexapro, Cipralex)
- Fluoxetine (Prozac)
- Fluvoxamine (Luvox)
- Paroxetine (Paxil, Seroxat)
- Sertraline (Zoloft, Lustral)
Discontinued
- Indalpine (Upstene)
- Zimelidine (Normud, Zelmid)
Never marketed
- Alaproclate (GEA-654)
- Cericlamine (JO-1017)
- Desmethylcitalopram
- Didesmethylcitalopram
- Femoxetine (FG-4963; Malexil)
- Ifoxetine (CGP-15,210-G)
- Omiloxetine
- Panuramine (WY-26,002)
- Pirandamine (AY-23,713)
- RTI-353
- Seproxetine ((S)-norfluoxetine)
Dual serotonin reuptake inhibitors and serotonin receptor modulators
Marketed
- Trazodone (Desyrel)
- Vilazodone (Viibryd)
- Vortioxetine (Trintellix)
Never marketed
- Cianopramine (Ro 11-2465)
- Litoxetine (SL-810,385)
- Lubazodone (YM-992, YM-35,995)
- SB-649,915
Serotonin reuptake inhibition as a weaker/unintended secondary effect
Marketed
- Dextromethorphan (DXM; Robitussin)
- Dextropropoxyphene (Darvon)
- Dimenhydrinate (Dramamine)
- Diphenhydramine (Benadryl)
- Mepyramine (pyrilamine) (Anthisan)
- Mifepristone (Korlym, Mifeprex)
Never marketed
- 4′-Fluorococaine (also a Dopamine reuptake inhibitor)
- Delucemine (also an NMDA antagonist)
- Mesembrenone (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna))
- Mesembrine (also a weak PDE4 inhibitor (found in Sceletium tortuosum (kanna))
- Roxindole (EMD-49,980) (also a 5-HT1A and D2-like receptor agonist)
References
References
- (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol..
- (2001). "Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine". Biol Psychiatry.
- (2014). "A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine". Expert Opin Pharmacother.
- (2013). "Psychologists' Desk Reference". Oxford University Press.
- (2011). "Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging". Pharmacopsychiatry.
- (2009). "Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram". Int Clin Psychopharmacol.
- (2007). "A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder". Exp. Neurol..
- (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". Br J Anaesth.
- (September 1999). "Effects of antihistamines on 3, 4-methylenedioxymethamphetamine-induced depletion of serotonin in rats". Synapse.
- (2014). "Mifepristone modulates serotonin transporter function". Neural Regen Res.
- link. (2017-08-21 [http://www.pat2pdf.org/pat2pdf/foo.pl?number=6,288,104 (PDF)])
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Serotonin reuptake inhibitor — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report